Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

NCT ID: NCT00023933

Last Updated: 2013-01-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-10-31

Brief Summary

Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer. Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Radiolabeled monoclonal antibody therapy may be effective treatment for colorectal cancer

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose of iodine I 131 monoclonal antibody CC49-deltaCH2 (deleted CH2 region) in patients with colorectal cancer.

II. Determine the toxic effects, plasma pharmacokinetics, whole body biodistribution, and conjugate stability of this drug in these patients.

III. Determine the ability of this drug to localize to tumor sites in these patients.

IV. Determine the immune response in patients treated with this drug.

OUTLINE: This is a dose-escalation study.

Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.

Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity.

Patients are followed weekly for a minimum of 7 weeks and then every 6 weeks until disease progression.

Conditions

Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (monoclonal antibody)

Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.

Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the MTD is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity.

Group Type: EXPERIMENTAL

iodine I 131 monoclonal antibody CC49-deltaCH2

Intervention Type: DRUG

Given IV

Interventions

iodine I 131 monoclonal antibody CC49-deltaCH2

Given IV

Intervention Type: DRUG

Other Intervention Names

131I-HuCC49-deltaCH2; 131I-MOAB CC49-deltaCH2

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed metastatic adenocarcinoma of the colon or rectum

• Not amenable to surgical resection
• Recurrent or persistent disease after standard surgery, radiotherapy, and chemotherapy, including fluorouracil and irinotecan
• TAG-72 positive
• Performance status - ECOG 0-2
• WBC greater than 3,500/mm^3
• Platelet count greater than 125,000/mm^3
• Hemoglobin greater than 10 g/dL
• No nucleated RBC or significant teardrop RBC morphology
• Bilirubin less than 1.5 mg/dL
• SGOT/SGPT less than 4 times normal
• Hepatitis B surface antigen negative
• Creatinine less than 2.0 mg/dL
• HIV negative
• No other malignancy within the past 5 years except basal cell skin cancer
• No allergy to iodine
• No detectable antibody to monoclonal antibody CC49
• Not pregnant or nursing
• Fertile patients must use effective contraception
• At least 3 weeks since prior immunotherapy and recovered
• No prior bone marrow or stem cell transplantation
• No other concurrent immunotherapy
• See Disease Characteristics
• At least 3 weeks since prior chemotherapy and recovered
• No concurrent chemotherapy
• See Disease Characteristics
• At least 3 weeks since prior radiotherapy and recovered
• No prior radiotherapy to more than 25% of red marrow
• No concurrent radiotherapy
• See Disease Characteristics
• At least 3 weeks since prior surgery and recovered

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ruby Meredith

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

Countries

United States

Other Identifiers

UAB 9846

Identifier Type: -

Identifier Source: secondary_id

CDR0000068877

Identifier Type: REGISTRY

Identifier Source: secondary_id

NCI-2012-02406

Identifier Type: -

Identifier Source: org_study_id